---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-060256"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:22:33.525934+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeuroOne raises ~$5.2M net in registered direct offering of 6M shares at $1.00/share

## Summary
- Offered and sold 6,037,500 shares (including full overallotment) at $1.00 per share raising gross ~$6.04M.
- Net proceeds of ~$5.215M after underwriting discounts and offering expenses.
- Proceeds to fund EVO sEEG commercial launch with Zimmer Biomet, FDA filing for OneRF ablation, and drug-delivery electrode design.
- Offering closed July 27, 2023; 90-day lock-up for insiders on further share sales.

## SEC filing metadata
- accession: 0001213900-23-060256
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390023060256/0001213900-23-060256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390023060256/ea182399-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-060256
- JSON: https://secwatch.observer/filing/0001213900-23-060256.json
- Plain text: https://secwatch.observer/filing/0001213900-23-060256.txt

## Key facts
- Material Agreements
  NEUROONE MEDICAL TECHNOLOGIES Corp entered into Underwriting Agreement with The Benchmark Company, LLC valued at approximately $5,214,875 (effective 2023-07-24).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: The Benchmark Company, LLC
  - Value: approximately $5,214,875
  - Effective: 2023-07-24
  source text: On July 24, 2023, NeuroOne Medical Technologies Corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with The Benchmark Company, LLC, as underwriter (the “Underwriter”), relating to the issuance and sale of 5,250,000 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $1.00 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1500198/000121390023060256/0001213900-23-060256-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.